Generic Name and Formulations:
Desonide 0.05%; crm.
Encore Dermatology, Inc.
Indications for TRIDESILON:
Apply thin film 2–4 times daily. Do not occlude. Reevaluate if no improvement after 2 weeks.
Treat infection if present or develop; discontinue until infection controlled. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use near eyes, or if hypersensitivity to corticosteroid, or pre-existing skin atrophy. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, burning, hypergylcemia, liver function abnormality; HPA axis suppression (esp. in children).
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies